| Moral issues of human-nonhuman primate neural grafting M Greene, K Schill, S Takahashi, A Bateman-House, T Beauchamp, ... SCIENCE-NEW YORK THEN WASHINGTON- 5733, 385, 2005 | 128 | 2005 |
| Ethical issues in gender-affirming care for youth LL Kimberly, KMB Folkers, P Friesen, D Sultan, GP Quinn, ... Pediatrics 142 (6), 2018 | 101 | 2018 |
| Safety issues in cell-based intervention trials L Dawson, AS Bateman-House, DM Agnew, H Bok, DW Brock, ... Fertility and sterility 80 (5), 1077-1085, 2003 | 94 | 2003 |
| Public stem cell banks: considerations of justice in stem cell research and therapy RR Faden, L Dawson, AS Bateman‐House, DM Agnew, H Bok, DW Brock, ... Hastings Center Report 33 (6), 13-27, 2003 | 85 | 2003 |
| Should patients in need be given access to experimental drugs? AL Caplan, A Bateman-House Expert Opinion on Pharmacotherapy 16 (9), 1275-1279, 2015 | 53 | 2015 |
| Medical Examination of Immigrants at Ellis Island A Bateman-House, A Fairchild AMA Journal of Ethics 10 (4), 235-241, 2008 | 47 | 2008 |
| The Federal Right to Try Act of 2017—A Wrong Turn for Access to Investigational Drugs and the Path Forward A Bateman-House, CT Robertson JAMA internal medicine 178 (3), 321-322, 2018 | 41 | 2018 |
| Right-to-Try Laws: Hope, Hype, and Unintended Consequences A Bateman-House, L Kimberly, B Redman, N Dubler, A Caplan Annals of internal medicine 163 (10), 796-797, 2015 | 40 | 2015 |
| Fecal microbiota transplantation: Uses, questions, and ethics Z Grigoryan, MJ Shen, SW Twardus, MM Beuttler, LA Chen, ... Medicine in Microecology 6, 100027, 2020 | 38 | 2020 |
| Gene therapy companies have an ethical obligation to develop expanded access policies L Kearns, CR Chapman, KI Moch, AL Caplan, T Watson, A McFadyen, ... Molecular Therapy 29 (4), 1367-1369, 2021 | 33* | 2021 |
| Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials AL Caplan, JR Teagarden, L Kearns, AS Bateman-House, E Mitchell, ... Journal of medical ethics 44 (11), 761-767, 2018 | 28 | 2018 |
| Pre-approval Access Terminology: A Cause for Confusion and a Danger to Patients LL Kimberly, MM Beuttler, M Shen, AL Caplan, A Bateman-House Therapeutic Innovation & Regulatory Science 51 (4), 494-500, 2017 | 26 | 2017 |
| Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways HF Lynch, A Bateman-House Journal of Law, Medicine & Ethics 48 (2), 365-372, 2020 | 24 | 2020 |
| What compassionate use means for gene therapies CR Chapman, KI Moch, A McFadyen, L Kearns, T Watson, P Furlong, ... Nature biotechnology 37 (4), 352-355, 2019 | 24 | 2019 |
| Helpful lessons and cautionary tales: How should COVID-19 drug development and access inform approaches to non-pandemic diseases? HF Lynch, A Caplan, P Furlong, A Bateman-House The American Journal of Bioethics 21 (12), 4-19, 2021 | 22 | 2021 |
| Academic Advocacy: Opportunities to Influence Health and Science Policy Under US Lobbying Law HF Lynch, A Bateman-House, SM Rivera Academic Medicine 95 (1), 44-51, 2020 | 16 | 2020 |
| Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses A Bateman-House, L Kearns nucleic acid therapeutics 32 (2), 111-117, 2022 | 14 | 2022 |
| Oversight of Right‐to‐Try and Expanded Access Requests for Off‐Trial Access to Investigational Drugs CR Chapman, J Eckman, AS Bateman‐House Ethics & Human Research 42 (1), 2-13, 2020 | 14 | 2020 |
| Improving Expanded Access in the United States: The Role of the Institutional Review Board KMB Folkers, A Bateman-House Therapeutic innovation & regulatory science 52 (3), 285-293, 2018 | 14 | 2018 |
| Bikes, helmets, and public health: decision-making when goods collide A Bateman-House American journal of public health 104 (6), 986-992, 2014 | 14 | 2014 |
Arthur CaplanProfessor of Medical Ethics, New York University Langone Medical CenterDirección de correo verificada de nyumc.org
